surfactant replacement therapy


Also found in: Acronyms.

surfactant replacement therapy

Neonatology Intratracheally administered bronchoalveolar fluid derived from calves–98% lipids, comprised of 90% phospholipid, especially dipalmitoyl-phosphatidylcholine and 2% apoproteins, which markedly improves gas exchange in premature infants; prophylactic bovine surfactant administered intratracheally ↓ need for neonatal respiratory support and ↑ survival of premature infants, especially < 30 wks. See Hyaline membrane disease.
Mentioned in ?
References in periodicals archive ?
4, who were candidate of exogenous surfactant administration by neonatologist, (9,10) were intubated for surfactant replacement therapy (Survanta, Abbott Comp, USA; 4 ml/kg via endotracheal tube).
This was due to either congenital anomalies, another respiratory disease other than RDS, asphyxia, extubated after one hour of INSURE method, or needed surfactant replacement therapy after 48 hours birth.
Surfactant replacement therapy for preterm and term neonates with respiratory distress.
Discovery's Surfactant Replacement Therapy is also in a Phase 2 clinical trial for Acute Respiratory Distress Syndrome in adults, a Phase 3 and a Phase 2 clinical trial for Meconium Aspiration Syndrome in full-term infants, and a Phase 1b clinical trial for asthma.
Surfactant replacement therapy is the primary focus in treating infants with HMD.
Questions involved in initiating surfactant replacement therapy include whether to use synthetic or natural surfactant.
However, the survival rate using modern intensive care procedures and treatments, including surfactant replacement therapy, approaches 90%.
We believe that our humanized Surfactant Replacement Therapy as an aerosol spray has the potential of relieving the obstruction in the airways associated with asthma.